New Zealand-owned medical cannabis company Greenfern Industries (GFI) has signed an exclusive distribution agreement with UK company Brains Bioceutical Corp (Brains) to sell their pharmaceutical grade cannabidiol (CBD) products in New Zealand.
This distribution agreement between GFI and Brains will allow Kiwi patients to access one of the world’s best brands of cannabinoid products, produced under EU-GMP (good manufacturing practice) compliance standards in the UK.
Greenfern director Dan Casey said with access to a full line of products, the distribution agreement between GFI and Brains will allow patients to gain greater access to pharmaceutical grade cannabinoid-based products.While the company is building its own research and extraction facilities, it will continue to distribute Brains’ products due to their sustainable quality and EU-GMP accreditation. Greenfern expects to have its own products ready for the market in about 12-24 months.
Brains manufactures natural, non-genetically modified, EU GMP-grade pharmaceutical-grade CBD from hemp plants at its manufacturing facility in the UK. The product produced at this facility is currently used as an API (active pharmaceutical ingredient) in various clinical research studies and special medicines around the globe.
Based in Taranaki, Greenfern aims to be the most environmentally friendly and sustainable medical cannabis company in New Zealand. The company holds a research licence to grow medical cannabis. They have a commercial growing licence application pending a security inspection from the Ministry of Health and are about to complete the first phase of their Normanby facility that will be powered by the adjacent hydro-electric power station.
Greenfern will begin distributing Brains’ products for sale in 2021.